Safety Study of BMS-844421 for Treatment of Hypercholesterolemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
AtherosclerosisHypercholesterolemia
Interventions
DRUG

BMS-844421

"Ready-to-use stock solution for SC and IV, Subcutaneous, 37.5 mg~SAD: Once, 1 Day~MAD: IV loading followed by 4 weekly doses, 29 Days"

DRUG

0.9% sodium chloride injection solution

"Injection solution, Subcutaneous, 37.5 mg~SAD: Once, 1 Day~MAD: IV loading followed by 4 weekly doses, 29 Days"

Trial Locations (1)

14050

Local Institution, Berlin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY